Adalimumab biosimilar (Wuhan Institute Of Biological)

阿达木单抗生物类似药（武汉生物）

Report date: 2025/08/11 15:06:44

Base Information

Drug NameAdalimumab biosimilar (Wuhan Institute Of Biological)
Drug Alias Name重组人抗TNF-α单抗（武汉生物）阿达木单抗生物仿制药（武汉生物）生爱宁
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisPsoriasisUveitis +[8] 
Global Approved IndicationsPlaque psoriasisPsoriasisUveitis +[8] 
Approved Indications in ChinaPlaque psoriasisPsoriasisUveitis +[8] 
Original Approved Country/TerritoryMainland China
Original Approved Date2025/08/05
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesWuhan Institute Of Biological Products Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesWuhan Institute Of Biological Products Co Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisUveitis +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A